China Endeavor Registry: A Registry With The Endeavor Zotarolimus Eluting Coronary Stent in China
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00793312|
Recruitment Status : Completed
First Posted : November 19, 2008
Last Update Posted : October 17, 2012
The primary objective is to document the acute and mid-term safety and overall clinical performance of the Endeavor(TM) Zotarolimus Eluting Coronary stent system in a "real world" Chinese patient population requiring stent implantation.
To assess the event rate in patient subgroups with specific clinical indications and/or vessel or lesion characteristics.
|Condition or disease|
|Coronary Artery Disease|
The safety and efficacy of the Endeavor(TM) Zotarolimus Eluting Coronary Stent System has been assessed in a series of studies, e.g. ENDEAVOR I and ENDEAVOR II. The stent is composed of a cobalt alloy and is coated with a proprietary drug compound zotarolimus that is designed to reduce restenosis.
This registry with the Endeavor(TM) Zotarolimus Eluting Coronary Stent System is being initiated 1) to expand the clinical knowledge base by including 'real world'patients in China and 2) to assess the event rate in Chinese patients known to have a higher risk of major adverse cardiac events, for example patients with diabetes mellitus, small vessels and long lesions.
In total the plan is to enroll about 2200 patients from 37 sites.
Follow-up will be one year for the main patients with cohort to collect acute and mid-term follow-up data, but will be extended to two years for certain patient subgroups.
|Study Type :||Observational|
|Actual Enrollment :||2210 participants|
|Official Title:||To Evaluate the 'Real World' Clinical Performance of the Medtronic Endeavor™ Zotarolimus Eluting Coronary Stent System in Chinese Patients, A Prospective, Multicenter Registry|
|Study Start Date :||November 2007|
|Actual Primary Completion Date :||September 2009|
|Actual Study Completion Date :||September 2010|
- MACE [ Time Frame: 12 Months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00793312
|Principal Investigator:||Jiyan Chen, Professor||Guangdong Provincial People's Hospital|
|Principal Investigator:||Yaling Han, Professor||Shenyang North Hospital|
|Principal Investigator:||Yong Huo, Professor||Peking University First Hospital|
|Principal Investigator:||Weimin Wang, Professor||Beijing People's Hospital|
|Principal Investigator:||Bo Xu, Director||Fu Wai Hospital, Beijing, China|